Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05421663 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

StatusActive, Not Recruiting
PhasePhase 1/2
Started2022-08-12
View on ClinicalTrials.gov ↗
This is a Phase 1b/2, multicenter, open-label, study of JNJ-90014496, an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).

Amendment history 4 changes detected by DataLookout

2026-08-29
Primary completion pushed: 2028-12-29 → 2041-07-30
2026-07-07
Trial status changed: Recruiting → Active, Not Recruiting
2026-07-07
Enrollment reduced: 439 → 166 participants
2026-06-06
Completion pushed: 2029-03-12 → 2041-07-30
Trial Details
NCT Number NCT05421663
Lead Sponsor Janssen Research & Development, LLC
Conditions Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Enrollment 166 participants
Start Date 2022-08-12
Primary Completion 2041-07-30 (estimated)
Study Completion 2041-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-28